ArticleThe Journal of clinical endocrinology and metabolism2021
Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma.
Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Pheochromocytoma unmasked by rapid deterioration of previously stable type 2 diabetes.JCEM case reports · 2026Article
- Bmal1 overexpression in suprachiasmatic nucleus protects from retinal neurovascular deficits in a mouse model of diabetes.Diabetologia · 2026Article
- The Role of Cortisol Secretion in Pheochromocytomas and Paragangliomas: Clinical and Perioperative Implications.The Journal of clinical endocrinology and metabolism · 2026Article
- Long-Term Persistence of Glycemic Dysregulation in Patients With a History of Pheochromocytoma/Paraganglioma.The Journal of clinical endocrinology and metabolism · 2025Article
- Inflammation-based Scores in Patients With Pheochromocytoma.The Journal of clinical endocrinology and metabolism · 2025Article
- Sex differences in management and outcomes in pheochromocytomas and paragangliomas.Frontiers in endocrinology · 2025Article
- Ectopic adrenocorticotropic hormone-secreting pheochromocytoma with severe metabolic disturbances: A case report.International journal of surgery case reports · 2024Article
- Article
- Review
- Catastrophic ACTH-secreting pheochromocytoma: an uncommon and challenging entity with multifaceted presentation.Endocrinology, diabetes & metabolism case reports · 2023Article
- Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.International journal of molecular sciences · 2023Review
- Unexplained Cachexia as a Presenting Symptom of Pheochromocytoma in a Geriatric Patient.JCEM case reports · 2023Article
- Factors associated with dysglycemia and its post-surgical resolution in patients with pheochromocytomas.Science China. Life sciences · 2023Article
- The Clinical Characteristics of Pheochromocytomas and Paragangliomas with Negative Catecholamines.Journal of clinical medicine · 2022Article
- A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction.Therapeutic advances in endocrinology and metabolism · 2022Article
- Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations inFrontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
contextPheochromocytomas and paragangliomas (PCC/PGL) are neuroendocrine tumors with discrete catecholamine profiles that cause incompletely understood metabolic and physiologic changes.
objectiveThe objective was to evaluate relationships between plasma catecholamines, body weight, and hemoglobin A1c (HbA1c). We hypothesized that individual catecholamines would correlate negatively with weight and glucose control.
designA retrospective cohort study was performed (1999-2020). Wilcoxon rank-sum tests compared nonparametric, continuous variables; mixed-effect linear modeling (MEM) evaluated relationships between catecholamines and weight or HbA1c. The median study duration was 54.2 months [interquartile range (IQR) 19.0-95.1].
settingTertiary academic hospital. PATIENTS: 360 patients were identified prospectively by referral to our center for management or surveillance of PCC/PGL. The median age was 59 years (IQR 45-67) and 56.4% (n = 203) were female.
main outcome measuresThe primary and secondary outcomes were weight and HbA1c, respectively.
resultsOn multivariable MEM, norepinephrine (P < 0.0005) negatively correlated with weight when all catecholamines and their derivatives were tried in the model, and normetanephrine (P < 0.0005) correlated when only metanephrines were included. In the surgical cohort (n = 272), normetanephrine decreased postoperatively and was inversely associated with weight (P < 0.0005). Elevated norepinephrine or normetanephrine at the study termination, indicative of metastatic and/or recurrent disease (MRD), correlated with weight loss. Norepinephrine and normetanephrine (P < 0.0005) directly correlated with HbA1c.
conclusionPlasma norepinephrine and its metabolite directly correlate with HbA1c and inversely correlate with weight in PCC/PGL. After resection, declining normetanephrine levels correlate with improving HbA1c despite an increase in patient body weight. Persistently elevated catecholamines and decreasing weight are observed in MRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.